Main Conference Day 1 (28th April 2026)Tuesday, 28 April 2026 - CET/CEST (Cent Europe Summer, GMT+2)

AAV vector manufacturing remains one of the most significant bottlenecks in gene therapy. Traditional cell-based production systems are slow, variable, and resource-intensive - relying on fragile biological processes developed decades ago. These inefficiencies not only hinder progress toward larger patient populations and new indications but also limit innovation in rare and ultra-rare diseases, where manufacturing costs can outweigh any commercial incentive to develop therapies. The result is a field constrained by biology, cost, and scale. Fuse Vectors is pioneering a fundamentally new approach: a cell-free, enzymatic system that assembles high-quality AAV vectors in hours, not weeks. This breakthrough forms the foundation of the Fuse Platform, comprising three integrated components. Fuse Cell-Free Technology eliminates the need for producer cells and enables direct, programmable AAV assembly. The Fuse Foundry leverages this speed and precision to allow partners and customers to rapidly prototype and select optimal vector candidates. Fuse Scale-Up, advancing toward GMP, extends these processes seamlessly to manufacturing scale: offering a consistent, economically viable route from discovery to clinic. We will share quantitative data demonstrating the efficiency, fidelity, and scalability of cell-free AAV production—achieving >99% full capsids in a single, 4-hour process and yields exceeding cell-based systems by more than tenfold. New in vivo benchmarking results, comparing cell-free and HEK-based AAV in disease-relevant models, will be presented for the first time. Together, these findings illustrate how removing biological constraints delivers step-change improvements in quality, reproducibility, and cost - redefining the path toward scalable and accessible gene therapy manufacturing.

• Mastering the development, calibration, and validation of a robust model for real-time measurement of critical parameters in reactor

• Successful integration of a RAMAN probe to creates a closed-loop, dynamic feeding strategy

• Real Results: How can in-line monitoring significantly reduce batch variability and improve consistency of product quality

• Overcoming practical challenges of long-term model maintenance within GMP environment

• EVs are rapidly growing, but with no established purification platform

• Current state-of-the-art purification strategies

• Pros and Cons of differing approaches:

  • Centrifugation

  • Filtration

  • Chromatography

• The future of EV purification: what will a platform look like?

This presentation explores how Artificial Intelligence and Machine Learning contribute differently to modern bioprocess optimization. Five industrially relevant showcases will be discussed - spanning upstream and downstream processes, from monoclonal antibodies to viral vectors, and from small-scale development to manufacturing scale. Emphasis will be placed on the digital transformation journey from manual development work toward fully autonomous biomanufacturing, highlighting solution paths that enable faster, more consistent, and intelligent process optimization across the product lifecycle.

Have a Solution for This Challenge?

This session is your platform to demonstrate leadership and technical expertise. Present your data, case studies, and innovative solutions to a targeted audience of senior scientists and engineers looking to solve hurdles in their production processes.

To learn more about sponsoring this session, contact us at Partners@informaconnectls.com